Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies

<div>Forest plot of proportion of patients not requiring a platelet transfusion or any rescue procedure, combined Baseline platelet count cohorts—pooled data from ADAPT-1 and ADAPT-2 (full analysis set). CI = confidence interval, MELD = model for end-stage liver disease. <sup>a</sup>Treatment difference = proportion of responders for avatrombopag−proportion of responders for placebo; 95% confidence interval is calculated based on normal approximation.</div>

International Journal of Hepatology

fig2

Figure 2

Figure 2: Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies 

Figure 2 | Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies 